+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Human placenta tissue lysate, Primary antibody: P07549(PGF Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 40 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P07549(PGF Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P07549(PGF Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

Placental Growth Factor (PGF), a member of the vascular endothelial growth factor (VEGF) family, is a glycoprotein primarily involved in angiogenesis and vascular remodeling. Initially identified for its role in placental development and pregnancy, PGF binds to VEGF receptor-1 (VEGFR-1) and neuropilin co-receptors, modulating endothelial cell proliferation, migration, and survival. Unlike VEGF-A, PGF exhibits limited mitogenic activity but plays a compensatory role in pathological angiogenesis when VEGF-A signaling is impaired. Its expression is upregulated in hypoxic or inflammatory conditions, contributing to diseases such as cancer, diabetic retinopathy, and preeclampsia.

PGF-targeting antibodies have emerged as therapeutic tools to inhibit pathological angiogenesis. By neutralizing PGF or blocking its interaction with receptors, these antibodies aim to suppress aberrant vascular growth without disrupting physiological VEGF-A functions, potentially reducing side effects like hypertension or impaired wound healing associated with broad VEGF inhibition. Preclinical studies highlight PGF antibodies' efficacy in tumor regression and retinopathy models, though clinical translation remains ongoing. Additionally, PGF is explored as a diagnostic biomarker; altered serum levels correlate with preeclampsia severity, aiding early detection. Challenges include optimizing selectivity and understanding context-dependent roles, as PGF may exhibit both pro- and anti-angiogenic effects in different tissues. Overall, PGF antibodies represent a promising, though complex, avenue for targeted anti-angiogenic therapies. (298 words)